66 related articles for article (PubMed ID: 20350485)
1. Treatment of ovarian cancer by monoclonal antibodies.
Mabuchi S; Kimura T
Discov Med; 2010 Mar; 9(46):197-203. PubMed ID: 20350485
[TBL] [Abstract][Full Text] [Related]
2. Use of monoclonal antibodies in the treatment of ovarian cancer.
Mabuchi S; Morishige K; Kimura T
Curr Opin Obstet Gynecol; 2010 Feb; 22(1):3-8. PubMed ID: 19770762
[TBL] [Abstract][Full Text] [Related]
3. [Monoclonal anti-idiotype antibodies in immunotherapy of ovarian carcinoma (MAb ACA125) and breast carcinoma (MAb ACA14C5)].
Wagner U; Köhler S; Prietl G; Giffels P; Schmidt-Nicolai S; Schlebusch H; Grünn U; Bender H; Biersack HJ; De Potter C; Krebs D; Wallwiener D
Zentralbl Gynakol; 1999; 121(4):190-5. PubMed ID: 10355096
[TBL] [Abstract][Full Text] [Related]
4. Preclinical studies and clinical utilization of monoclonal antibodies in epithelial ovarian cancer.
Frederick PJ; Straughn JM; Alvarez RD; Buchsbaum DJ
Gynecol Oncol; 2009 Jun; 113(3):384-90. PubMed ID: 19232697
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibody therapy of ovarian cancer.
Nicodemus CF; Berek JS
Expert Rev Anticancer Ther; 2005 Feb; 5(1):87-96. PubMed ID: 15757441
[TBL] [Abstract][Full Text] [Related]
6. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
[TBL] [Abstract][Full Text] [Related]
7. Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer.
Berek J; Taylor P; McGuire W; Smith LM; Schultes B; Nicodemus CF
J Clin Oncol; 2009 Jan; 27(3):418-25. PubMed ID: 19075271
[TBL] [Abstract][Full Text] [Related]
8. Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC.
Maione P; Gridelli C; Troiani T; Ciardiello F
Oncologist; 2006 Mar; 11(3):274-84. PubMed ID: 16549812
[TBL] [Abstract][Full Text] [Related]
9. The role of anti-epidermal growth factor receptor monoclonal antibody monotherapy in the treatment of metastatic colorectal cancer.
Bouché O; Beretta GD; Alfonso PG; Geissler M
Cancer Treat Rev; 2010 Feb; 36 Suppl 1():S1-10. PubMed ID: 20189053
[TBL] [Abstract][Full Text] [Related]
10. The future of targeted therapies in ovarian cancer.
Banerjee S; Gore M
Oncologist; 2009 Jul; 14(7):706-16. PubMed ID: 19592450
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide.
Bianco C; Bianco R; Tortora G; Damiano V; Guerrieri P; Montemaggi P; Mendelsohn J; De Placido S; Bianco AR; Ciardiello F
Clin Cancer Res; 2000 Nov; 6(11):4343-50. PubMed ID: 11106252
[TBL] [Abstract][Full Text] [Related]
12. Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors.
Thaker PH; Yazici S; Nilsson MB; Yokoi K; Tsan RZ; He J; Kim SJ; Fidler IJ; Sood AK
Clin Cancer Res; 2005 Jul; 11(13):4923-33. PubMed ID: 16000591
[TBL] [Abstract][Full Text] [Related]
13. Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer.
Van Cutsem E
Oncologist; 2006 Oct; 11(9):1010-7. PubMed ID: 17030643
[TBL] [Abstract][Full Text] [Related]
14. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.
Ciardiello F; Bianco R; Damiano V; Fontanini G; Caputo R; Pomatico G; De Placido S; Bianco AR; Mendelsohn J; Tortora G
Clin Cancer Res; 2000 Sep; 6(9):3739-47. PubMed ID: 10999768
[TBL] [Abstract][Full Text] [Related]
15. Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications.
Tortora G; Ciardiello F; Gasparini G
Nat Clin Pract Oncol; 2008 Sep; 5(9):521-30. PubMed ID: 18594498
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor: a promising target in solid tumours.
Laskin JJ; Sandler AB
Cancer Treat Rev; 2004 Feb; 30(1):1-17. PubMed ID: 14766123
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibodies therapies for ovarian cancer.
Leone Roberti Maggiore U; Bellati F; Ruscito I; Gasparri ML; Alessandri F; Venturini PL; Ferrero S
Expert Opin Biol Ther; 2013 May; 13(5):739-64. PubMed ID: 23373587
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibodies in gynecological cancer: a critical point of view.
Bellati F; Napoletano C; Gasparri ML; Visconti V; Zizzari IG; Ruscito I; Caccetta J; Rughetti A; Benedetti-Panici P; Nuti M
Clin Dev Immunol; 2011; 2011():890758. PubMed ID: 22235224
[TBL] [Abstract][Full Text] [Related]
19. Oregovomab: an investigational agent for the treatment of advanced ovarian cancer.
Pietragalla A; Duranti S; Daniele G; Nero C; Ciccarone F; Lorusso D; Fagotti A; Scambia G
Expert Opin Investig Drugs; 2021 Feb; 30(2):103-110. PubMed ID: 33423551
[No Abstract] [Full Text] [Related]
20. Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer.
Grisham RN; Berek J; Pfisterer J; Sabbatini P
Immunotherapy; 2011 Feb; 3(2):153-62. PubMed ID: 21322756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
